Approved use of the drug has been expanded to include treatment of patients with hepatocellular carcinoma who have been treated with sorafenib.
The FDA suggests that clinicians should consider alternatives to eluxadoline in this population.
The drug reduces the frequency of diarrhea by inhibiting the production of serotonin by carcinoid tumors.
The drug is indicated to induce remission in adults with active, mild to moderate ulcerative colitis and to maintain remission of ulcerative colitis.
The oral medication is taken once per day and works in the upper GI tract to stimulate secretion of intestinal fluid, supporting regular bowel function.